What's Happening?
The upcoming 2026 Joint Review of the United States-Mexico-Canada Agreement (USMCA) presents an opportunity to strengthen pharmaceutical manufacturing and supply chains in North America. The COVID-19 pandemic exposed weaknesses in global pharmaceutical supply chains,
highlighting North America's reliance on foreign suppliers for active pharmaceutical ingredients (APIs) and finished drugs. The review will consider cooperative reforms to address these dependencies, with a focus on reshoring production and enhancing regional coordination. The U.S. is also conducting a Section 232 national security review of the pharmaceutical sector, which may recommend tariffs on imports to reduce foreign dependence.
Why It's Important?
Strengthening pharmaceutical supply chains is crucial for ensuring public health security and reducing reliance on foreign suppliers. The USMCA review provides a platform for regional cooperation, which is essential for addressing vulnerabilities exposed by the pandemic. By enhancing self-sufficiency in pharmaceutical production, North America can improve its resilience to global disruptions and geopolitical tensions. The potential for tariffs on pharmaceutical imports raises concerns about higher consumer costs and access to essential medicines, highlighting the need for balanced policy approaches that consider both security and affordability.
What's Next?
The USMCA review will likely focus on creating a shared early-warning system for drug shortages and investing in API and generic drug production capacity within North America. Regulatory harmonization and mutual recognition of manufacturing standards could also be prioritized to streamline regional integration. The review's outcomes will be critical in shaping the future of North America's pharmaceutical sector and its ability to respond to global challenges. Policymakers will need to balance national security objectives with economic and public health considerations to ensure equitable access to medicines.
